Vision Our vision is to be the leading voice in digestive disease diagnosis, instrumenting change to empower every healthcare provider and improve the life of every patient. Mission By working in partnership with industry experts we will collaborate, innovate and educate to provide the most efficient means of diagnosis for digestive diseases, empowering healthcare providers, improving patients’ quality of life and, ultimately, saving lives.
Innovative gut microbiota test to identify dysbiosis from faecal samples. The test employs 48 highly specific probes targeting predetermined multiplex targets and single nucleotide differences in the 16S rRNA gene of bacteria. The cutting-edge, high throughput technology detects over 300 bacterial species across taxonomic levels in a single reaction, providing efficient and accurate microbiota characterisation.
Determination of total anti-infliximab antibodies Infliximab is a recombinant protein used to treat inflammatory bowel disease (IBD). The protein can induce humoral immune responses and lead to anti-drug antibody formation, a major cause of loss of drug response. IDKmonitor Infliximab Total Anti-drug ELISA kit is a ‘drug tolerant’ assay that enables the detection of anti-drug antibodies in the presence of circulating drug.
Determination of total anti-adalimumab antibodies Adalimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, a major cause of loss of drug response. The IDKmonitor Adalimumab Total Anti-drug ELISA kit is a ‘drug tolerant’ assay that enables the detection of anti-drug antibodies in the presence of circulating dru…
